MedTrace Logo

Trial of Subretinal Injection of (rAAV2-VMD2-hMERTK)

NCT01482195 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-01-26

Study results available
· View outcomes & findings →

Summary

This study was to assess the safety of gene transfer via subretinal administration of rAAV2-VMD2-hMERTK in subjects with MERTK-associated retinitis pigmentosa (RP).

Conditions

Interventions

BIOLOGICAL

Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus

The study is an open-label, dose-escalation, phase I clinical trial of subretinal administration of rAAV2-VMD2-hMERTK in patients with retinitis pigmentosa due to MERTK mutation.

Sponsors & Collaborators

  • King Faisal Specialist Hospital & Research Center

    collaborator OTHER

  • King Khaled Eye Specialist Hospital

    lead OTHER_GOV

Principal Investigators

  • Fowzan S Alkuraya, MD · King Faisal Specialist Hospital & Research Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2013-08-31
Completion
2019-08-31

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01482195 on ClinicalTrials.gov